Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000201 · ClinicalTrials.gov registry record · Phase 2

Pharmacological Modulation of Cocaine Effects - 1

A Phase 2 study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00000201: Completed Phase 2 study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

NCT00000201 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000201, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.

Conditions Studied

Cocaine-Related Disorders

Interventions

  • DRUG Selegiline

Study Locations (1)

Maryland

  • Johns Hopkins University (BPRU) Bayview Campus - Baltimore

Trial Details

FieldValue
Est. Completion 2001-12
Phase Phase 2
National Institute on Drug Abuse (NIDA)

335 total trials

What the finished NCT00000201 record still lists

NCT00000201 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Selegiline is the first listed.

NCT00000201 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00000201 about?

NCT00000201 is a clinical study titled "Pharmacological Modulation of Cocaine Effects - 1". The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.

What is the current status of trial NCT00000201?

This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.

What conditions does trial NCT00000201 study?

This clinical trial studies the following conditions: Cocaine-Related Disorders.

What interventions are being tested in trial NCT00000201?

The interventions under investigation include: Selegiline (DRUG).

Who is sponsoring clinical trial NCT00000201?

This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000201 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cocaine-Related Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00000201, the US trial registry maintained by the National Library of Medicine. NCT00000201 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.